Real-world study ‘reassuring’ on DOACs
A major real-world study in primary care has provided initial reassurance that direct oral anticoagulants (DOACs) are a safe alternative to warfarin.
UK researchers tracked nearly 200,000 patients prescribed either warfarin, apixaban, rivaroxaban or dabigatran for an average of 3-11 months between 2011 and 2016.
Half had diagnosed AF, while, significantly, the other half were taking the drugs for other indications including to prevent venous thromboembolism or ischaemic stroke after joint replacement or fracture. Few studies have looked at patients taking